Abstract
Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening disorder characterized by antibodies to Platelet Factor 4 (PF4)-polyanion complexes which cause thrombocytopenia and thrombosis. Currently used technically-simple frontline assays such as the PF4-polyanion enzyme-linked immunosorbent assays (ELISAs) lack specificity, and more accurate functional assays such as the serotonin release assay (SRA) and PF4-dependent P-selectin expression assay (PEA) have long turnaround times due to technical complexity and availability only in the reference laboratory setting. There is a critical need for accurate near-patient functional testing to guide patient management, but a key barrier to attaining this goal is the short-term viability of platelets. Here, we detail a process of platelet cryopreservation that renders them viable for at least one year and show that PF4-treated cryopreserved platelets, when coupled with ELISA-based measurement of thrombospondin-1 release (a platelet α-granule protein), detects pathogenic HIT antibodies with high accuracy. Furthermore, testing of a cohort of non-pathogenic HIT antibodies that were strongly reactive in PF4/polyanion ELISA but negative in functional assays demonstrated negative results in the thrombospondin-1 release assay, confirming high specificity of this technique. These findings have the potential to transform the diagnostic testing paradigm in HIT by making in-hospital functional testing available for rapid and accurate diagnosis.
Competing Interest Statement
CJ reports pending/issued patents (Versiti BloodCenter of Wisconsin, Retham Technologies) and reports equity ownership and employment in Retham Technologies. R.K.P. reports honoraria for advisory board participation from CSL Behring, Genentech, Bayer Healthcare AG, HEMA Biologics, Instrumentation Laboratory, and Merck. AP reports pending/issued patents (Mayo Clinic, Retham Technologies and Versiti BloodCenter of Wisconsin), equity ownership in Retham Technologies, and serves on the advisory board of Veralox Therapeutics.
Funding Statement
This work was supported, in part, by National Institutes of Health grant HL147734 (C.J), HL133479 (A.P) and through a grant from the Therapeutic Accelerator Program of the Drug Discovery Center at Medical College of Wisconsin and Wisconsin Economic Development Corporation's (WEDC): Targeted Industry projects.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mayo Clinic Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conference Presentation: The data were presented in part at the International Society of Thrombosis and Hemostasis Annual Meeting in July 17-21, 2021.
Data Availability
Data presented in the manuscript with be shared with legitimate parties, upon reasonable request.
